Literature DB >> 28329197

Systematic Review, Meta-analysis, and Cost-effectiveness of Treatment of Latent Tuberculosis to Reduce Progression to Multidrug-Resistant Tuberculosis.

Suzanne M Marks1, Sundari R Mase1, Sapna Bamrah Morris1.   

Abstract

BACKGROUND.: Evidence-based recommendations for treating persons having presumed latent tuberculosis (LTBI) after contact to infectious multidrug-resistant (MDR) tuberculosis (TB) are lacking because published data consist of small observational studies. Tuberculosis incidence in persons treated for latent MDR -TB infection is unknown. METHODS.: We conducted a systematic review of studies published 1 January 1994-31 December 2014 to analyze TB incidence, treatment completion and discontinuation, and cost-effectiveness. We considered contacts with LTBI effectively treated if they were on ≥1 medication to which their MDR-TB strain was likely susceptible. We selected studies that compared treatment vs nontreatment outcomes and performed a meta-analysis to estimate the relative risk of TB incidence and its 95% confidence interval. RESULTS.: We abstracted data from 21 articles that met inclusion criteria. Six articles presented outcomes for contacts who were treated compared with those not treated for MDR-LTBI; 10 presented outcomes only for treated contacts, and 5 presented outcomes only for untreated contacts. The estimated MDR-TB incidence reduction was 90% (9%-99%) using data from 5 comparison studies. We also found high treatment discontinuation rates due to adverse effects in persons taking pyrazinamide-containing regimens. Cost-effectiveness was greatest using a fluoroquinolone/ethambutol combination regimen. CONCLUSIONS.: Few studies met inclusion criteria, therefore results should be cautiously interpreted. We found a reduced risk of TB incidence with treatment for MDR-LTBI, suggesting effectiveness in prevention of progression to MDR-TB, and confirmed cost-effectiveness. However, we found that pyrazinamide-containing MDR-LTBI regimens often resulted in treatment discontinuation due to adverse effects. Published by Oxford University Press for the Infectious Diseases Society of America 2017. This work is written by (a) US Government employee(s) and is in the public domain in the US.

Entities:  

Keywords:  contacts; cost.; multidrug-resistant; treatment; tuberculosis

Mesh:

Substances:

Year:  2017        PMID: 28329197      PMCID: PMC5543758          DOI: 10.1093/cid/cix208

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  33 in total

Review 1.  Lack of evidence to support policy development for management of contacts of multidrug-resistant tuberculosis patients: two systematic reviews.

Authors:  M J van der Werf; M W Langendam; A Sandgren; D Manissero
Journal:  Int J Tuberc Lung Dis       Date:  2012       Impact factor: 2.373

2.  Management of pediatric contacts of multidrug resistant tuberculosis in the United Kingdom.

Authors:  Bhanu Williams; Shiva Ramroop; Pooja Shah; Laura Anderson; Sreena Das; Anna Riddell; Susan Liebeschuetz; Jolanta Bernatoniene; Delane Shingadia; Beate Kampmann
Journal:  Pediatr Infect Dis J       Date:  2013-08       Impact factor: 2.129

3.  Management of latent tuberculosis infection in child contacts of multidrug-resistant tuberculosis.

Authors:  Felice C Adler-Shohet; Julie Low; Michael Carson; Haimanot Girma; Jasjit Singh
Journal:  Pediatr Infect Dis J       Date:  2014-06       Impact factor: 2.129

4.  High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis.

Authors:  A B Younossian; T Rochat; J-P Ketterer; J Wacker; J-P Janssens
Journal:  Eur Respir J       Date:  2005-09       Impact factor: 16.671

5.  Evaluation of young children in contact with adult multidrug-resistant pulmonary tuberculosis: a 30-month follow-up.

Authors:  H Simon Schaaf; Robert P Gie; Magdalene Kennedy; Nulda Beyers; Peter B Hesseling; Peter R Donald
Journal:  Pediatrics       Date:  2002-05       Impact factor: 7.124

6.  High tuberculosis prevalence in children exposed at home to drug-resistant tuberculosis.

Authors:  F Amanullah; M Ashfaq; S Khowaja; A Parekh; N Salahuddin; I Lotia-Farrukh; A J Khan; M C Becerra
Journal:  Int J Tuberc Lung Dis       Date:  2014-05       Impact factor: 2.373

7.  Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis.

Authors:  Tina Papastavros; Lisa R Dolovich; Anne Holbrook; Lori Whitehead; Mark Loeb
Journal:  CMAJ       Date:  2002-07-23       Impact factor: 8.262

8.  Fluoroquinolone Therapy for the Prevention of Multidrug-Resistant Tuberculosis in Contacts. A Cost-Effectiveness Analysis.

Authors:  Gregory J Fox; Olivia Oxlade; Dick Menzies
Journal:  Am J Respir Crit Care Med       Date:  2015-07-15       Impact factor: 21.405

9.  Treatment for LTBI in contacts of MDR-TB patients, Federated States of Micronesia, 2009-2012.

Authors:  S Bamrah; R Brostrom; F Dorina; L Setik; R Song; L M Kawamura; A Heetderks; S Mase
Journal:  Int J Tuberc Lung Dis       Date:  2014-08       Impact factor: 2.373

10.  Adverse events in healthy individuals and MDR-TB contacts treated with anti-tuberculosis drugs potentially effective for preventing development of MDR-TB: a systematic review.

Authors:  Miranda W Langendam; Edine W Tiemersma; Marieke J van der Werf; Andreas Sandgren
Journal:  PLoS One       Date:  2013-01-11       Impact factor: 3.240

View more
  22 in total

1.  Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.

Authors:  Payam Nahid; Sundari R Mase; Giovanni Battista Migliori; Giovanni Sotgiu; Graham H Bothamley; Jan L Brozek; Adithya Cattamanchi; J Peter Cegielski; Lisa Chen; Charles L Daley; Tracy L Dalton; Raquel Duarte; Federica Fregonese; C Robert Horsburgh; Faiz Ahmad Khan; Fayez Kheir; Zhiyi Lan; Alfred Lardizabal; Michael Lauzardo; Joan M Mangan; Suzanne M Marks; Lindsay McKenna; Dick Menzies; Carole D Mitnick; Diana M Nilsen; Farah Parvez; Charles A Peloquin; Ann Raftery; H Simon Schaaf; Neha S Shah; Jeffrey R Starke; John W Wilson; Jonathan M Wortham; Terence Chorba; Barbara Seaworth
Journal:  Am J Respir Crit Care Med       Date:  2019-11-15       Impact factor: 21.405

Review 2.  The burden of multidrug-resistant tuberculosis in children.

Authors:  H E Jenkins; C M Yuen
Journal:  Int J Tuberc Lung Dis       Date:  2018-05-01       Impact factor: 2.373

Review 3.  Treatment of Latent Tuberculosis Infection-An Update.

Authors:  Moises A Huaman; Timothy R Sterling
Journal:  Clin Chest Med       Date:  2019-12       Impact factor: 2.878

4.  Treatment as prevention and other interventions to reduce transmission of multidrug-resistant tuberculosis.

Authors:  R R Nathavitharana; P Lederer; D B Tierney; E Nardell
Journal:  Int J Tuberc Lung Dis       Date:  2019-04-01       Impact factor: 2.373

Review 5.  Treatment of Drug-Resistant Tuberculosis.

Authors:  Sundari R Mase; Terence Chorba
Journal:  Clin Chest Med       Date:  2019-12       Impact factor: 2.878

6.  Risk Factors for Adverse Events in Household Contacts Prescribed Preventive Treatment for Drug-resistant Tuberculosis Exposure.

Authors:  Amyn A Malik; Mercedes C Becerra; Timothy L Lash; Lisa M Cranmer; Saad B Omer; Junaid Fuad; Sara Siddiqui; Farhana Amanullah; Maria Jaswal; Naseem Salahuddin; Salmaan Keshavjee; Hamidah Hussain; Neel R Gandhi
Journal:  Clin Infect Dis       Date:  2021-05-18       Impact factor: 20.999

Review 7.  Treatment of Latent Tuberculosis Infection.

Authors:  Patrick Tang; James Johnston
Journal:  Curr Treat Options Infect Dis       Date:  2017-09-22

Review 8.  Is Chemoprophylaxis for Child Contacts of Drug-Resistant TB Patients Beneficial? A Systematic Review.

Authors:  C Padmapriyadarsini; Mrinalini Das; Sharath Burugina Nagaraja; Mahalakshmi Rajendran; Richard Kirubakaran; Sarabjit Chadha; Prathap Tharyan
Journal:  Tuberc Res Treat       Date:  2018-04-02

9.  Levofloxacin versus placebo for the prevention of tuberculosis disease in child contacts of multidrug-resistant tuberculosis: study protocol for a phase III cluster randomised controlled trial (TB-CHAMP).

Authors:  James A Seddon; Anthony J Garcia-Prats; Susan E Purchase; Muhammad Osman; Anne-Marie Demers; Graeme Hoddinott; Angela M Crook; Ellen Owen-Powell; Margaret J Thomason; Anna Turkova; Diana M Gibb; Lee Fairlie; Neil Martinson; H Simon Schaaf; Anneke C Hesseling
Journal:  Trials       Date:  2018-12-20       Impact factor: 2.279

10.  Association between vitamin D and latent tuberculosis infection in the United States: NHANES, 2011-2012.

Authors:  Cheng-Yi Wang; Yin-Lan Hu; Ya-Hui Wang; Cheng-Hsin Chen; Chih-Cheng Lai; Kun-Lun Huang
Journal:  Infect Drug Resist       Date:  2019-07-22       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.